GLP-1 drugs show potential to prevent and treat sepsis through anti-inflammatory and organ-protective mechanisms | Research

The takeaway

Preclinical evidence shows GLP-1 agonists reduce inflammation, oxidative stress, mitochondrial dysfunction, and endothelial damage in sepsis, with clinical data suggesting reduced infection complications and mortality, positioning them as adjunctive sepsis therapy.

Multi-organ sepsis protection
GLP-1 drugs reduce inflammation, oxidative stress, and mitochondrial damage while preserving blood vessel integrity—addressing the key pathological mechanisms of sepsis

What the researchers found

Preclinical: GLP-1 agonists ↓inflammation, ↓oxidative stress, ↓mitochondrial dysfunction, preserved endothelial integrity. Animal: ↓organ damage, ↑survival. Clinical: ↓infection complications, ↓mortality. Mechanisms: anti-inflammatory + cardioprotective + neuroprotective.

Why it matters

Sepsis kills 11 million people annually with limited effective treatments. GLP-1 drugs' multi-organ protective properties could provide adjunctive therapy for this devastating condition.

How the study worked

Narrative review of preclinical and clinical evidence for GLP-1 agonists in sepsis.

What this study cannot tell us

Mostly preclinical evidence. Clinical data is observational. Sepsis is heterogeneous. Optimal GLP-1 dosing for sepsis unknown. No prospective sepsis trials.

How to read the evidence

Narrative review of preclinical + observational clinical evidence. Promising but needs prospective trials.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs' pleiotropic protective effects (anti-inflammatory, anti-oxidative, endothelial, mitochondrial) are exactly what sepsis treatment needs. This may be one of the most impactful repurposing opportunities.

Questions still open

Should GLP-1 drugs be tested in sepsis prevention trials?
Would acute GLP-1 administration during sepsis provide benefit?
Is the sepsis benefit from chronic anti-inflammatory effects or acute organ protection?

Common questions

Could GLP-1 drugs prevent sepsis?

Emerging evidence suggests they might. GLP-1 drugs reduce inflammation, protect blood vessels, and preserve organ function—all critical in sepsis. Clinical data from diabetic patients shows those on GLP-1 drugs have lower rates of severe infections and infection-related death.

How would GLP-1 drugs help in sepsis?

Sepsis damages organs through excessive inflammation, oxidative stress, and blood vessel breakdown. GLP-1 drugs address all three: they reduce inflammatory cytokines, protect mitochondria (cellular energy), and maintain endothelial integrity (blood vessel function). In animal models, this translates to less organ damage and better survival.

Read the original research

The Potential of Using Glucagon-Like Peptide-1 Receptor Agonists in Sepsis.

Cardiology in review

View on PubMed ↗Publisher’s paper ↗

Citation

Tomy, Noel; Shwartzman, Benjamin; Frishman, William H. (2025). The Potential of Using Glucagon-Like Peptide-1 Receptor Agonists in Sepsis.. Cardiology in review. https://doi.org/10.1097/CRD.0000000000000998